The Influence of Body Size Descriptors on the Estimation of Kidney Function in Normal Weight, Overweight, Obese, and Morbidly Obese Adults

2012 ◽  
Vol 46 (3) ◽  
pp. 317-328 ◽  
Author(s):  
Eun Jung Park ◽  
Manjunath P Pai ◽  
Ting Dong ◽  
Jialu Zhang ◽  
Chia-Wen Ko ◽  
...  
Keyword(s):  
Body Size ◽  
Kidney Function ◽  
Normal Weight ◽  
Morbidly Obese ◽  
Obese Adults

scholarly journals Implications for IV posaconazole dosing in the era of obesity

2020 ◽  
Vol 75 (4) ◽  
pp. 1006-1013 ◽  
Author(s):  
Roeland E Wasmann ◽  
Cornelis Smit ◽  
Marieke H van Donselaar ◽  
Eric P A van Dongen ◽  
René M J Wiezer ◽  
...  
Keyword(s):  
Body Size ◽  
Fungal Infections ◽  
Oral Treatment ◽  
Total Body Weight ◽  
Normal Weight ◽  
Therapeutic Drug ◽  
Morbidly Obese ◽  
Population Pharmacokinetic ◽  
Antimicrobial Drugs ◽  
Starting Point

Abstract Background The prevalence of obesity has shown a dramatic increase over recent decades. Obesity is associated with underdosing of antimicrobial drugs for prophylaxis and treatment. Posaconazole is a broad-spectrum triazole antifungal drug licensed for prophylaxis and treatment of invasive fungal infections. It is unclear how posaconazole should be dosed in obese patients. Methods We performed a prospective study investigating the pharmacokinetics of posaconazole in morbidly obese (n = 16) and normal-weight (n = 8) subjects, with a weight ranging between 61.4 and 190 kg, after a 300 or 400 mg IV dose. Population pharmacokinetic modelling was used to assess the effect of body size on posaconazole pharmacokinetics. ClinicalTrials.gov Identifier: NCT03246386. Results Total body weight best predicted changes in CL and V. Model-based simulations demonstrated that, for treatment of fungal infections, a daily IV dose of 300 mg will result in a PTA of ≥90% in individuals up to 140 kg, after which both twice daily loading and the daily maintenance dose should be increased to 400 mg. For prophylaxis, a 300 mg IV dose is adequate in patients up to 190 kg. Conclusions Body size has a significant impact on posaconazole CL and V, resulting in a lower exposure in obese subjects compared with normal-weight subjects. For therapeutic use of posaconazole, a dose increase is required in patients above 140 kg. For prophylaxis, a 300 mg IV dose is adequate. For oral treatment, these recommendations can act as a starting point followed by therapeutic drug monitoring.

Body image in obese adults

1981 ◽  
Vol 11 (1) ◽  
pp. 147-154 ◽  
Author(s):  
G. D. Pearlson ◽  
L. H. Flournoy ◽  
M. Simonson ◽  
P. R. Slavney
Keyword(s):  
Body Image ◽  
Body Size ◽  
Weight Reduction ◽  
Age Of Onset ◽  
Normal Weight ◽  
Obese Women ◽  
Adult Obesity ◽  
Body Width ◽  
Obese Adults ◽  
Obese Subjects

SYNOPSISData were gathered on 38 obese women and 16 obese men attending a weight-reduction programme and on an equal number of normal weight controls, regarding accuracy of perception of body width in 4 regions, as well as attitudes towards body size. Obese subjects, particularly women, tended to overestimate body width and to dislike their bodies, but neither of these factors predicted success in losing weight. Age of onset of obesity was not related to degree of adult obesity or to accuracy of estimation of body width.

scholarly journals Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients

2011 ◽  
Vol 55 (9) ◽  
pp. 4006-4011 ◽  
Author(s):  
Manjunath P. Pai ◽  
Anne N. Nafziger ◽  
Joseph S. Bertino
Keyword(s):  
Body Weight ◽  
Body Size ◽  
Kidney Function ◽  
Volume Of Distribution ◽  
Normal Weight ◽  
Adult Patients ◽  
World Health ◽  
Lean Body Weight ◽  
Pharmacokinetic Data ◽  
Male Adult

ABSTRACTAminoglycosides are an important class of agents that are used in combination antimicrobial regimens to treat bacterial pathogens. Dosing of aminoglycosides is typically based on total body weight. However, the most appropriate alternative body size descriptor for dosing aminoglycosides at the extremes of weight (underweight and obese) is not known. Also, the predictive performance of newer formulas to assess kidney function, such as the modification of diet in renal disease (MDRD) and chronic kidney disease-epidemiology (CKD-EPI) equations compared to the Cockcroft-Gault equation to predict aminoglycoside clearance, is not known. We sought to examine dosing of aminoglycosides across the extremes of weight using a variety of formulas to assess kidney function. Pharmacokinetic data were obtained from a set of prospectively collected data (1982 to 2003) of 2,073 (53.5% male) adult patients that included 497 tobramycin- and 1,576 gentamicin-treated cases. The median (minimum, maximum) age, weight, and body mass index were 66 (18, 98) years, 70.0 (29.7, 206.7) kg, and 24.4 (11.3, 73.8) kg/m2, respectively. The percentage of underweight, normal-weight, overweight, and obese cases based on the World Health Organization classification were 8.8%, 45.5%, 26.5%, and 19.2%, respectively. The aminoglycoside volume of distribution was normalized to several alternative body size descriptors. Only lean body weight estimated by the method of S. Janmahasatian et al. (Clin. Pharmacokinet. 44:1051–1065, 2005) normalized the volume of distribution for both tobramycin and gentamicin across all weight strata, with the estimate being approximately 0.45 liter/kg. Aminoglycoside dosing can be simplified across all weight strata with the use of lean body weight. The CKD-EPI equation best predicts aminoglycoside clearance.

scholarly journals Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults

2019 ◽  
Vol 74 (4) ◽  
pp. 978-985 ◽  
Author(s):  
Roeland E Wasmann ◽  
Cornelis Smit ◽  
Rob ter Heine ◽  
Simon E Koele ◽  
Eric P H van Dongen ◽  
...  
Keyword(s):  
Normal Weight ◽  
Morbidly Obese ◽  
Target Attainment ◽  
Obese Adults

scholarly journals Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Saira Khan ◽  
K. Y. Wolin ◽  
R. Pakpahan ◽  
R. L. Grubb ◽  
G. A. Colditz ◽  
...  
Keyword(s):  
Body Size ◽  
Benign Prostatic Hyperplasia ◽  
Life Course ◽  
Early Life ◽  
Prostate Volume ◽  
Late Life ◽  
Later Life ◽  
Normal Weight ◽  
Prostatic Hyperplasia ◽  
The Life Course

Abstract Background Existing evidence suggests that there is an association between body size and prevalent Benign Prostatic Hyperplasia (BPH)-related outcomes and nocturia. However, there is limited evidence on the association between body size throughout the life-course and incident BPH-related outcomes. Methods Our study population consisted of men without histories of prostate cancer, BPH-related outcomes, or nocturia in the intervention arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) (n = 4710). Associations for body size in early- (age 20), mid- (age 50) and late-life (age ≥ 55, mean age 60.7 years) and weight change with incident BPH-related outcomes (including self-reported nocturia and physician diagnosis of BPH, digital rectal examination-estimated prostate volume ≥ 30 cc, and prostate-specific antigen [PSA] concentration > 1.4 ng/mL) were examined using Poisson regression with robust variance estimation. Results Men who were obese in late-life were 25% more likely to report nocturia (Relative Risk (RR): 1.25, 95% Confidence Interval (CI): 1.11–1.40; p-trendfor continuous BMI < 0.0001) and men who were either overweight or obese in late-life were more likely to report a prostate volume ≥ 30 cc (RRoverweight: 1.13, 95% CI 1.07–1.21; RRobese: 1.10, 95% CI 1.02–1.19; p-trendfor continuous BMI = 0.017) as compared to normal weight men. Obesity at ages 20 and 50 was similarly associated with both nocturia and prostate volume ≥ 30 cc. Considering trajectories of body size, men who were normal weight at age 20 and became overweight or obese by later-life had increased risks of nocturia (RRnormal to overweight: 1.09, 95% CI 0.98–1.22; RRnormal to obese: 1.28, 95% CI 1.10–1.47) and a prostate volume ≥ 30 cc (RRnormal to overweight: 1.12, 95% CI 1.05–1.20). Too few men were obese early in life to examine the independent effect of early-life body size. Later-life body size modified the association between physical activity and nocturia. Conclusions We found that later-life body size, independent of early-life body size, was associated with adverse BPH outcomes, suggesting that interventions to reduce body size even late in life can potentially reduce the burden of BPH-related outcomes and nocturia.

scholarly journals DNA methylation profile of genes involved in inflammation and autoimmunity correlates with vascular function in morbidly obese adults

Epigenetics ◽  
2021 ◽  
pp. 1-17
Author(s):  
Mohamed M. Ali ◽  
Dina Naquiallah ◽  
Maryam Qureshi ◽  
Mohammed Imaduddin Mirza ◽  
Chandra Hassan ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Vascular Function ◽  
Methylation Profile ◽  
Morbidly Obese ◽  
Obese Adults ◽  
Dna Methylation Profile

scholarly journals Awareness and knowledge about weight status and management: results from the 1 d sensitization campaign ‘Obesity Day’ in northern Italy

2011 ◽  
Vol 14 (10) ◽  
pp. 1813-1822 ◽  
Author(s):  
Michela Barichella ◽  
Alexis E Malavazos ◽  
Giuseppe Fatati ◽  
Emanuele Cereda
Keyword(s):  
Physical Activity ◽  
Weight Management ◽  
Health Care Professionals ◽  
Weight Control ◽  
Weight Status ◽  
Normal Weight ◽  
Cross Sectional Survey ◽  
Obese Adults ◽  
Cross Sectional

AbstractObjectiveTo evaluate the awareness and knowledge about weight status and its management.DesignA 1 d cross-sectional survey. Basic anthropometric assessments (weight, height, BMI and waist circumference) and a self-administered questionnaire were considered.SettingNineteen Clinical Nutrition or Endocrinology and Metabolic Disorders Units or Dietetics Services in the Italian region of Lombardy.SubjectsAll adults attending the ‘Obesity Day’ initiative.ResultsA total of 914 participants (605 female and 309 male) were recruited. Although most of the participants (83·5 %) considered obesity to be a disease, 38·5 % were likely to misperceive their weight status. In particular, 38·8 % of normal-weight adults believed themselves to be overweight, whereas 71·1 % and 37·5 % of classes I and II/III obese adults classified themselves as being overweight and mildly obese, respectively. However, most of the overweight (90·2 %), mildly (96·8 %) and moderately/severely obese adults (99·1 %) recognized the need to lose weight. In all, 37·8 % of the sample underestimated the role of physical activity in weight management. Interestingly, only 17·2 % of dieters (previous or current) declared being advised by their doctor to lose weight. Multivariate models revealed that higher age, low education and higher BMI were important determinants of poor weight control and management. In addition, previous dieting appeared not to provide better knowledge, whereas the role of physical activity was recognized mainly by those practising it.ConclusionsThe present study suggests that in Italy knowledge about weight management should be improved not only in the general population but also among health-care professionals. To confirm this finding, there is now the rationale for a nationally representative survey. New educational programmes can be designed on the basis of the information collected.

Sign in / Sign up

Export Citation Format

Share Document